In this episode of the "Innovations in Cardiology" series, host Dr. Dipti Itchhaporia, former president of the ACC, is joined by Dr. C. Michael Gibson, CEO of the Baim Institute for Research, for an insightful discussion on the latest advancements and future directions in cardiovascular innovation for 2024. Dr. Itchhaporia and Dr. Gibson explore strategies to enhance efficiency in cardiovascular research, with a focus on direct-to-patient trials. They delve into how this approach can be optimized to better target patients and improve outcomes. Dr. Gibson shares details about a groundbreaking platform being developed to support long-term follow-up studies, enabling patient monitoring for up to 20 years through persistent follow-up alerts. The conversation also touches on key findings from the Apple Heart Study, particularly in relation to atrial fibrillation detection via the Apple Watch, and the differences in compliance rates between older and younger patients. Additionally, they discuss the upcoming results of the Heartline Study, which focuses on patients aged 65 and older. Looking ahead, Dr. Itchhaporia and Dr. Gibson reflect on the future of cardiovascular care, including the potential for personalized care plans tailored to each patient. They consider the timeline for integrating this approach into clinical practice, potential barriers to implementation, and the significant opportunities it presents for improving patient outcomes. If you have any questions or suggestions for topics to cover on the Radcliffe Podcast, please email [email protected].

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related